At ProAct, we continue to enable affordable access to biosimilars and help ensure a smooth transition for patients starting these innovative products. Our thoughtful and comprehensive approach to include inflammatory biosimilars on our ...
On March 20, 2025, Johnson & Johnson’s Tremfya® (guselkumab) received FDA approval for a label expansion for the treatment of Crohn’s Disease (CD). Tremfya® is the first and only interleukin (IL)-23 inhibitor offering both subcutaneous ...
A new oral weight loss medication by Eli Lilly, Orforglipron, showed promising results in a phase 2 trial published in the New England Journal of Medicine in June 2023. The highest dose of the drug resulted in approximately 15% weight loss ...
On March 7, 2025, the US Food and Drug Administration (FDA) approved Celltrion’s Omlyclo® (omalizumab-igec) as the first interchangeable biosimilar to Novartis’ Xolair® (omalizumab). Omlyclo is approved for the same indications as ...
The US Food and Drug Administration (FDA) has determined the shortage of glucagon-like peptide 1 (GLP-1) medication, semaglutide, is resolved. Semaglutide injection products have been on the FDA shortage list since 2022. The FDA ...